Recent Updates
Recently added Catalysts
PEPG Negative Sentiment Score: 25/100

PepGen Inc. Sued for Securities Law Violations – Investors Should Contact The Gross Law Firm Before August 8, 2025 to Discuss Your Rights – PEPG

Key Takeaway: PepGen Inc. (NASDAQ: PEPG) faces a class-action lawsuit for alleged securities law violations related to its lead product candidate, PGN-EDO51. The complaint claims that the company issued false statements regarding the effectiveness and safety of PGN-EDO51, and that the phase two CONNECT2 study suffered from deficiencies. As a result, there are concerns about the likelihood of halting the study and overstated clinical prospects. Shareholders are encouraged to register for the class action by August 8, 2025.

Market Sentiment Analysis

CONCERNS & RISKS

  • The lawsuit alleges misleading statements regarding PGN-EDO51's effectiveness and safety.
  • There are claims that the CONNECT2 study may have safety issues affecting FDA approval.
  • Concerns arise that PepGen may need to halt the CONNECT2 study.
  • The allegations suggest that public statements made by the company were false and materially misleading.

Full Press Release Details

NEW YORK, June 18, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of PepGen Inc. (NASDAQ: PEPG).
Shareholders who purchased shares of PEPG during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.
CLASS PERIOD: March 7, 2024 to March 3, 2025
ALLEGATIONS: The complaint alleges that during the class period, Defendants issued materially false and/or misleading statements and/or failed to disclose that: (i) the Company’s lead product candidate, PGN-EDO51, was less effective and safe than defendants had led investors to believe; (ii) phase two, CONNECT2 study was dangerous or otherwise deficient for purposes of U.S. Food and Drug Administration (“FDA”) approval; (iii) as a result of all the foregoing, PepGen was likely to halt the CONNECT2 study, and PGN-EDO51’s clinical, regulatory, and commercial prospects were overstated; and (iv) as a result, defendants’ public statements were materially false and misleading at all relevant times.
DEADLINE: August 8, 2025 Shareholders should not delay in registering for this class action. Register your information here: https://securitiesclasslaw.com/securities/pepgen-inc-loss-submission-form/?id=153444&from=3
NEXT STEPS FOR SHAREHOLDERS: Once you register as a shareholder who purchased shares of PEPG during the timeframe listed above, you will be enrolled in a portfolio monitoring software to provide you with status updates throughout the lifecycle of the case. The deadline to seek to be a lead plaintiff is August 8, 2025. There is no cost or obligation to you to participate in this case.
WHY GROSS LAW FIRM? The Gross Law Firm is a nationally recognized class action law firm, and our mission is to protect the rights of all investors who have suffered as a result of deceit, fraud, and illegal business practices. The Gross Law Firm is committed to ensuring that companies adhere to responsible business practices and engage in good corporate citizenship. The firm seeks recovery on behalf of investors who incurred losses when false and/or misleading statements or the omission of material information by a company lead to artificial inflation of the company's stock. Attorney advertising. Prior results do not guarantee similar outcomes.
15 West 38th Street, 12th floor
Phone: (646) 453-8903

Tags

Frequently Asked Questions

What is the class period for PepGen Inc. shareholders?

The class period for PepGen Inc. shareholders is from March 7, 2024, to March 3, 2025.

What allegations are made against PepGen Inc.?

The allegations claim that PepGen misled investors about product efficacy and safety, and that the CONNECT2 study was deficient.

When is the deadline to register for the class action?

The deadline to register for the class action is August 8, 2025.

Do shareholders need to be lead plaintiffs to recover?

No, shareholders do not need to be lead plaintiffs to participate in any recovery.

How can shareholders get updates on their case?

Shareholders will receive updates through portfolio monitoring software once they register.

Last updated: Jun 18, 2025